[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100519914":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":12,"centralContacts":25,"locations":35,"responsibleParty":47,"collaborators":51,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":12,"eligibilityCriteria":60,"healthyVolunteers":61,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":12,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":77,"whyStopped":12,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Assuta Ashdod Hospital","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"hysteroscopic myomectomy without misoprostol","NO_INTERVENTION","Patients undergoing hysteroscopic myomectomy that will be randomized to no intervention before the procedure.",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Misoprostol group","EXPERIMENTAL","Patients undergoing hysteroscopic myomectomy will be randomized to 400 mcg of misoprostol sublingual before the procedure.",[18],"Drug: Misoprostol 400 Microgram Oral Tablet",[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":12},"DRUG","Misoprostol 400 Microgram Oral Tablet","S.L misoprostol 400 mcg",[14],[26,31],{"name":27,"role":28,"phone":29,"phoneExt":12,"email":30},"oshri barel","CONTACT","972 55 938 2117","oshrib@assuta.co.il",{"name":32,"role":28,"phone":33,"phoneExt":12,"email":34},"alona doron lalehzari","972 50 880 7991","alonado@assuta.co.il",[36],{"facility":37,"status":12,"city":38,"state":12,"zip":12,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":12},"Assuta Ashdod University Hospital","Ashdod","Israel","IL",{"type":42,"coordinates":43},"Point",[44,45],34.64966,31.79213,{"lat":45,"lon":44},{"type":48,"investigatorFullName":49,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":12,"oldOrganization":12},"PRINCIPAL_INVESTIGATOR","Oshri Barell","Head of Gynecology Division, Department of Obstetrics and Gynecology. Assuta Ashdod University Hospital",[52],{"name":53,"class":6},"Assuta Medical Center","100519914","phase-4-use-of-misoprostol-in-hysteroscopic-myomectomy-100519914",false,"NCT06049745","Use of Misoprostol in Hysteroscopic Myomectomy","Use of Misoprostol in Hysteroscopic Myomectomy, a Randomized Peospective Trial","Inclusion Criteria:\n\n* women between the ags of 20 years- 55 years, inclusive\n* undergoing hysteroscopic myomectomy\n* submucosal fibroid less than 40 mm (type 0, 1 and 2)\n* up to 2 submucosal fibroids\n* patients are able to provide written informed consent\n\nExclusion Criteria:\n\n* post menopausal women\n* inability to perform operative hysteroscopy under anesthesia in the past due to cervical stenosis\n* previous PID or documented tubal occlusion\n* positive BHCG test\n* inability to consent due to cognitive or language barrier\n* allergy to misoprostole\n* severe COPD, asthma or cardiac disease",true,"FEMALE","20 Years","55 Years",{"count":66,"type":67},200,"ESTIMATED","INTERVENTIONAL",[70],"PHASE4","Hysteroscopic myomectomy is typically suitable for myomas measuring under 4 cm in size. The utilization of misoprostol before the procedure can facilitate uterine access, decrease fluid absorption, and reduce blood loss, consequently leading to a decrease in the overall procedure time. In this randomized trial, the investigators aim to investigate the impact of misoprostol administration and its effects on each of the mentioned parameters.",[73],"Hysteroscopic Myomectomy",[75,76],"hysteroscopic myomectomy","misoprostol","NOT_YET_RECRUITING","2023-09-16",{"date":80,"type":81},"2023-09-22","ACTUAL",{"date":83,"type":67},"2023-11",{"date":85,"type":67},"2026-10",{"name":5,"class":6},1]